Purchase Option

$ 4400
$ 4000
$ 6000

Sepsis Disease Pipeline Drugs

  Sepsis Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018  


Sepsis is a potentially life-threatening or medical emergency condition in which the immune systems overrides its response to an infection. Sepsis develops when the chemicals are released into the bloodstream which causes the cascade of eventsthat lead to the inflammation throughout the body. In most of the cases, it may lead to the septic shock, which is medical emergency. According to Center for Disease Control and Prevention (CDC), more than 1.5 million people get Sepsis each year in U.S. and 250,000 people die each year

Sepsis can quickly progress to septic shock and may lead to death. A number of medications are used to treat the Sepsis including painkillers, vasoactive medications to improve blood pressure, insulin, corticosteroids and antibiotics via IV route.



By route of administration, sepsis pipeline drugs are segmented into

  • Oral
  • Parenteral
  • Others

By Trial Phase, Sepsis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

By Company, Sepsis pipeline drugs are segmented as:

  • Bristol-Myers Squibb (U.S.)
  • Eisai Co., Ltd. (Japan)
  • Shionogi & Company, Limited (Japan)
  • Adrenomed AG (Germany)
  • Ferring Holding SA (Switzerland)
  • TiGenix (Belgium)
  • Others

Space Analysis:

  • In December 2017, Adrenomed AG, announced today that the first patient with early septicshock has been dosed in the ADR-02 Phase-II study (AdrenOSS-2, NCT03085758)conducted in Germany, Belgium, France and the Netherlands.
  • In January 2017, TiGenix NV announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).

Report Description:

Sepsis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Sepsis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Sepsis disease pipeline drugs development. This report studies the dynamics of the Sepsis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Sepsis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases



PBI Location Map

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']


  • Bristol-Myers Squibb (U.S.)
  • Eisai Co., Ltd. (Japan)
  • Shionogi & Company, Limited (Japan)
  • Adrenomed AG (Germany)
  • Ferring Holding SA (Switzerland)
  • TiGenix (Belgium)

Adjacent Markets